oxaliplatin
Selected indexed studies
- PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. (Nat Commun, 2023) [PMID:37024475]
- USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. (J Exp Clin Cancer Res, 2025) [PMID:40069750]
- Oxaliplatin: Detection and Management of Hypersensitivity Reactions. (Clin J Oncol Nurs, 2019) [PMID:30682002]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. (2023) pubmed
- USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. (2025) pubmed
- Oxaliplatin: Detection and Management of Hypersensitivity Reactions. (2019) pubmed
- Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. (2025) pubmed
- Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis. (2024) pubmed
- Oxaliplatin-safety profile: neurotoxicity. (2003) pubmed
- Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review. (2021) pubmed
- [Oxaliplatin neurotoxicity]. (2006) pubmed
- [Oxaliplatin-induced peripheral neuropathy: how to create a barrier?]. (2020) pubmed
- Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial. (2025) pubmed